Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
HECTOROL is an injectable small-molecule vitamin D analog approved in 2000 for treating secondary hyperparathyroidism in patients with chronic kidney disease stage 5. The drug works by binding to vitamin D receptors to reduce PTH synthesis and increase calcium absorption, addressing metabolic complications of renal failure.
Product nearing end of exclusivity with minimal disclosed spending; brand team likely focused on defending legacy position against growing generic and branded competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
Worked on HECTOROL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings indicate minimal hiring and team growth; roles on this product are primarily defensive/maintenance focused rather than launch or expansion phase. Career development on HECTOROL is limited to navigating product decline, cost management, and potential transition to LOE strategies.